Yasuyuki Okumura1,2, Masahide Usami3, Takashi Okada4, Takuya Saito5, Hideki Negoro6, Noa Tsujii7, Junichi Fujita8, Junzo Iida9. 1. 1 Research Department, Institute for Health Economics and Policy , Association for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan . 2. 2 Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science , Tokyo, Japan . 3. 3 Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine , Ichikawa, Japan . 4. 4 Department of Child and Adolescent Psychiatry, Nagoya University Graduate School of Medicine , Nagoya, Japan . 5. 5 Department of Child and Adolescent Psychiatry, Faculty of Medicine, Hokkaido University , Sapporo, Japan . 6. 6 Department of Professional Development in Education, Graduate School of Professional Development in Education, Nara University of Education , Nara, Japan . 7. 7 Department of Neuropsychiatry, Kindai University Faculty of Medicine , Osaka, Japan . 8. 8 Department of Child Psychiatry, Yokohama City University Hospital , Yokohama, Japan . 9. 9 Department of Human Development, Faculty of Nursing, Nara Medical University , Kashihara, Japan .
Abstract
OBJECTIVE: We aimed to evaluate glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy using a nationwide claims database. METHODS: A retrospective 15-month cohort study was conducted using the National Database of Health Insurance Claim Information and Specified Medical Checkups in Japan. Patients aged ≤18 years, who were newly prescribed antipsychotics between April 2014 and March 2015, were followed up for 450 days. Outcomes were the use of glucose and prolactin testing through 15 months after drug initiation (index date) with consideration of persistence with antipsychotic therapy. The incidence proportion of patients monitored was assessed within the following four time windows: baseline (between 30 days before the index date and the index date), at 1-3 months (between 1 and 90 days after the index date), at 4-9 months (between 91 and 270 days after the index date), and at 10-15 months (between 271 and 450 days after the index date). RESULTS: Of 43,608 new users in 6620 medical institutions, the percentage of persistent antipsychotic users was 46.4% at 90 days, 29.7% at 270 days, and 23.8% at 450 days after the index date. The proportion of patients who received monitoring within the baseline period was 13.5% (95% confidence interval [CI], 13.2-13.8) for glucose and 0.6% (95% CI, 0.5-0.6) for prolactin, respectively. The proportion of patients who received glucose monitoring at all time windows decreased to 0.9%. The proportion of patients who received prolactin monitoring by the second time window decreased to 0.1%. CONCLUSIONS: Our study shows that monitoring for glucose and prolactin is infrequent in children and adolescents initiating antipsychotic therapy. Strategies for physicians, patients, and guardians are needed to overcome the barriers in glucose and prolactin monitoring.
OBJECTIVE: We aimed to evaluate glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy using a nationwide claims database. METHODS: A retrospective 15-month cohort study was conducted using the National Database of Health Insurance Claim Information and Specified Medical Checkups in Japan. Patients aged ≤18 years, who were newly prescribed antipsychotics between April 2014 and March 2015, were followed up for 450 days. Outcomes were the use of glucose and prolactin testing through 15 months after drug initiation (index date) with consideration of persistence with antipsychotic therapy. The incidence proportion of patients monitored was assessed within the following four time windows: baseline (between 30 days before the index date and the index date), at 1-3 months (between 1 and 90 days after the index date), at 4-9 months (between 91 and 270 days after the index date), and at 10-15 months (between 271 and 450 days after the index date). RESULTS: Of 43,608 new users in 6620 medical institutions, the percentage of persistent antipsychotic users was 46.4% at 90 days, 29.7% at 270 days, and 23.8% at 450 days after the index date. The proportion of patients who received monitoring within the baseline period was 13.5% (95% confidence interval [CI], 13.2-13.8) for glucose and 0.6% (95% CI, 0.5-0.6) for prolactin, respectively. The proportion of patients who received glucose monitoring at all time windows decreased to 0.9%. The proportion of patients who received prolactin monitoring by the second time window decreased to 0.1%. CONCLUSIONS: Our study shows that monitoring for glucose and prolactin is infrequent in children and adolescents initiating antipsychotic therapy. Strategies for physicians, patients, and guardians are needed to overcome the barriers in glucose and prolactin monitoring.
Entities:
Keywords:
antipsychotics; diabetes; metabolic monitoring; quality of care; side effects
Authors: Ángel L Montejo; Celso Arango; Miguel Bernardo; José L Carrasco; Benedicto Crespo-Facorro; Juan J Cruz; Javier Del Pino; Miguel A García Escudero; Clemente García Rizo; Ana González-Pinto; Ana I Hernández; Manuel Martín Carrasco; Fermin Mayoral Cleries; Jaqueline Mayoral van Son; M Teresa Mories; Isabella Pachiarotti; Salvador Ros; Eduard Vieta Journal: Rev Psiquiatr Salud Ment Date: 2016-02-24 Impact factor: 3.318
Authors: Marsha A Raebel; Robert Penfold; Ann W McMahon; Marsha Reichman; Susan Shetterly; Glenn Goodrich; Susan Andrade; Christoph U Correll; Tobias Gerhard Journal: Pediatrics Date: 2014-10-06 Impact factor: 7.124
Authors: Mariken Dinnissen; Andrea Dietrich; Judith H van der Molen; Anne M Verhallen; Ynske Buiteveld; Suzanne Jongejan; Pieter W Troost; Jan K Buitelaar; Barbara J van den Hoofdakker; Pieter J Hoekstra Journal: J Clin Psychopharmacol Date: 2021 Jan/Feb 01 Impact factor: 3.118
Authors: Lenneke Minjon; Ivona Brozina; Toine C G Egberts; Eibert R Heerdink; Els van den Ban Journal: Front Psychiatry Date: 2021-02-25 Impact factor: 4.157
Authors: Lenneke Minjon; Els van den Ban; Marloes T Bazelier; Arief Lalmohamed; Toine C G Egberts; Eibert R Heerdink Journal: J Child Adolesc Psychopharmacol Date: 2021-10-07 Impact factor: 2.576